Saturday, September 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 27, 2025

Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035

View original at globenewswire.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 Ottawa, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • North America holds 55% revenue share of ADC market in 2024

    80% confidence

  • IV route accounts for 90% of ADC administration in 2024

    80% confidence

  • Generic/biosimilar ADCs are the fastest growing drug type segment

    80% confidence

  • Hematologic cancers represent 35% of ADC therapeutic area market in 2024

    80% confidence

  • Hospital pharmacies and oncology centers represent 70% of ADC distribution in 2024

    80% confidence

  • Cleavable linkers represent 60% of ADC linker market share in 2024

    80% confidence

  • Global antitumor ADC drugs market will grow from $8.33B in 2026 to $24.75B in 2035 at 12.86% CAGR

    80% confidence

  • Solid tumors represent the fastest growing therapeutic area for ADCs

    80% confidence

  • Branded ADC drugs represent 75% market share in 2024

    80% confidence

  • Cytotoxic payloads represent 70% of ADC payload market share in 2024

    80% confidence

  • Asia-Pacific is the fastest growing ADC market region

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 — Source | Via News | Via News